To hear about similar clinical trials, please enter your email below

Trial Title: Galectin-3 in Papillary Thyroid Carcinoma

NCT ID: NCT05699590

Condition: Galactin 3-thyroid Carcinoma

Conditions: Official terms:
Carcinoma
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Retrospective

Summary: Thyroid cancer is a common head and neck malignancy. It is the most common endocrine tumor in the body accounting for 1% of all cancers worldwide. The incidence of thyroid cancer varies worldwide. Most countries have reported an upward trend in its incidence. Thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated carcinoma (< 1%) and anaplastic carcinoma (< 2%). Papillary thyroid carcinomas (PTCs) are the most commonly encountered thyroid malignancies. The diagnosis of PTC is based on the special nuclear features such as overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and nuclear grooves. However, it is often difficult to differentiate PTC from benign papillary thyroid hyperplasia . As differentiation between benign or malignant thyroid lesions has clinical, therapeutic, and prognostic significance, it is necessary to make accurate diagnosis by using biomarkers. Recently, a large number of immunohistochemical (IHC) markers have been studied to assist in differentiating non-neoplastic lesions from malignant thyroid lesions. CK19, galectin-3, TG, Ki67, BRAF, calcitonin, HBME-1, TTF-1, and RET are some of the examples of these IHC markers. Galectin-3 is a 31-kDa β-galactoside binding lectin. It has been shown to be expressed by several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell adhesion and in cell-matrix interactions.

Criteria for eligibility:

Study pop:
Formalin fixed and paraffin embedded prostatic tissue blocks from 70 patients

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: 1. Thyroidectomy specimens both hemithyroidectomy and total thyroidectomy. 2. All the studied cases include sufficient materials for the immunohistochemical study. 3. Complete clinical data Exclusion Criteria: 1. Patients with recurrence of the primary tumor. 2. Patients with a history of preoperative chemotherapy and/or radiotherapy. 3. Insufficient or tiny tissue biopsies

Gender: All

Minimum age: 20 Years

Maximum age: 90 Years

Start date: March 2023

Completion date: June 2023

Lead sponsor:
Agency: Sohag University
Agency class: Other

Source: Sohag University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05699590

Login to your account

Did you forget your password?